|
LIVE WEBINAR: Thursday, March 2, 2023, 5:00 PM – 6:00 PM Eastern Time (ET)
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology A Multitumor CME/MOC-Accredited Live Webinar Series
Join us on Thursday, March 2nd for this CME/MOC-accredited webinar Faculty
Matthew Milowsky, MD George Gabriel and Frances Gable Villere Distinguished Professor Vice Chief for Research and Education Section Chief, Genitourinary Oncology UNC Division of Oncology Co-Lead, Clinical and Translational Research Co-Director, Urologic Oncology Program UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
Thomas Powles, MBBS, MRCP, MD
Director of Barts Cancer Institute Queen Mary University of London London, United Kingdom Moderator Neil Love, MD Research To Practice Miami, Florida Thursday, March 2, 2023 Topics to Be Discussed
Target Audience Learning Objectives
CE Credit Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Milowsky — Advisory Committee and Consulting Agreement: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: ALX Oncology, Arvinas, Bristol-Myers Squibb Company, Clovis Oncology, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics Inc, Seagen Inc; Stock Options/Ownership — Public Company: Gilead Sciences Inc, Merck, Pfizer Inc; Nonrelevant Financial Relationship: Alliance for Clinical Trials in Oncology, Alliance Foundation Trials LLC, Elsevier (Co-Editor-in-Chief, Clinical Genitourinary Cancer), Hoosier Cancer Research Network Inc, Medscape (educational videos). Prof Powles — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |